Results Suggest Formulation Potentially Suitable for At-Home Administration Ketabon Also Releases In-Depth Data from Phase 2 KET01 Trial MUNICH, Germany,…
-- BROADWAY Phase 3 trial enrollment completed; on-track to report topline data for Phase 3 BROOKLYN and BROADWAY trials in…
Announced Dosing of First Patient in Pivotal STRIVE-ON Phase 3 Randomized Trial for GTX-104 Completed $7.5 Million Private Placement Equity…
Topline data results from the pivotal STRIDE study are expected in December 2023IRVINE, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) --…
Psychedelic Science 2023 was the breakthrough conference in psychedelics over 5 days in June 2023 in Denver, CO. Hosted by…
Hamilton, Bermuda, Nov. 10, 2023 (GLOBE NEWSWIRE) -- November 10, 2023 -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq:CYTO),…
Attributes 9,623% Revenue Growth to the exceptional clinical performance and unique technology of the Nalu Neurostimulation System in treating unmet…
TORONTO and HOUSTON, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTC: MDNAF),…
-- Blocking of α5β1 integrin has been shown to improve motor function and increase survival in the SOD1G93A mouse model of…
Jupiter, Florida--(Newsfile Corp. - November 9, 2023) - My Crew Doses Inc., (the "Company" or "MCD"), an American PhD-led brand…